Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?

por Duric, V M, Fallowfield, L J, Saunders, C, Houghton, J, Coates, A S, Stockler, M R
Publicado 2005

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer

por Lee, C K, Stockler, M R, Coates, A S, Gebski, V, Lord, S J, Simes, R J
Publicado 2010

Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer

por Stockler, M R, Tattersall, M H N, Boyer, M J, Clarke, S J, Beale, P J, Simes, R J
Publicado 2006

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

por Tebbutt, N C, Cummins, M M, Sourjina, T, Strickland, A, Van Hazel, G, Ganju, V, Gibbs, D, Stockler, M, Gebski, V, Zalcberg, J
Publicado 2010

Long-term outcome of radiological-guided insertion of implanted central venous access port devices (CVAPD) for the delivery of chemotherapy in cancer patients: institutional experi...

por Vardy, J, Engelhardt, K, Cox, K, Jacquet, J, McDade, A, Boyer, M, Beale, P, Stockler, M, Loneragan, R, Dennien, B, Waugh, R, Clarke, S J
Publicado 2004

Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer

por King, M T, Viney, R, Smith, D P, Hossain, I, Street, D, Savage, E, Fowler, S, Berry, M P, Stockler, M, Cozzi, P, Stricker, P, Ward, J, Armstrong, B K
Publicado 2012

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer

por Mahon, K L, Qu, W, Devaney, J, Paul, C, Castillo, L, Wykes, R J, Chatfield, M D, Boyer, M J, Stockler, M R, Marx, G, Gurney, H, Mallesara, G, Molloy, P L, Horvath, L G, Clark, S J
Publicado 2014

Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study

por Zhang, A Y, Judson, I, Benson, C, Wunder, J S, Ray-Coquard, I, Grimer, R J, Quek, R, Wong, E, Miah, A B, Ferguson, P C, Dufresne, A, Teh, J Y H, Stockler, M, Tattersall, M H N
Publicado 2017

Correction: Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study

por Zhang, A. Y., Judson, I., Benson, C., Wunder, J. S., Ray-Coquard, I., Grimer, R. J., Quek, R., Wong, E., Miah, A. B., Ferguson, P. C., Dufresne, A., Teh, J. Y. H., Stockler, M., Tattersall, M. H. N.
Publicado 2018

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

por Lin, H-M, Castillo, L, Mahon, K L, Chiam, K, Lee, B Y, Nguyen, Q, Boyer, M J, Stockler, M R, Pavlakis, N, Marx, G, Mallesara, G, Gurney, H, Clark, S J, Swarbrick, A, Daly, R J, Horvath, L G
Publicado 2014

Somatostatin receptor expression, tumour response and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide

por Cebon, J, Findlay, M, Hargreaves, C, Stockler, M, Thompson, P, Boyer, M, Roberts, S, Poon, A, Scott, A M, Kalff, V, Garas, G, Dowling, A, Crawford, D, Ring, J, Basser, R, Strickland, A, Macdonald, G, Green, M, Nowak, A, Dickman, B, Dhillon, H, Gebski, V
Publicado 2007

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer

por Mahon, K L, Lin, H-M, Castillo, L, Lee, B Y, Lee-Ng, M, Chatfield, M D, Chiam, K, Breit, S N, Brown, D A, Molloy, M P, Marx, G M, Pavlakis, N, Boyer, M J, Stockler, M R, Daly, R J, Henshall, S M, Horvath, L G
Publicado 2015